Related Experiment Videos
Second-line therapy in colorectal cancer
1GI Oncology Vanderbilt University, Nashville, Tennessee, USA. jordan.berlin@mcmail@vanderbilt.edu
Oncology (Williston Park, N.Y.)
|February 24, 2001
Summary
Second-line therapy for colorectal cancer is evolving. This article explores the efficacy of oxaliplatin (Eloxatin) as a second-line chemotherapy option for patients with advanced colorectal cancer.
Area of Science:
- Oncology
- Gastroenterology
Background:
- Second-line therapy is an emerging strategy in gastrointestinal oncology.
- Retreatment with fluorouracil (5-FU) is common, but novel agents are increasingly used.
Purpose of the Study:
- To evaluate the use and efficacy of oxaliplatin (Eloxatin) as a second-line therapy for colorectal cancer patients.
Main Methods:
- This article focuses on the clinical application and effectiveness of oxaliplatin.
- Limited data on toxicity profiles of oxaliplatin regimens are presented.
Main Results:
- Oxaliplatin demonstrates efficacy as a second-line treatment option.
- Further research is needed to fully understand its role.
Conclusions:
- Oxaliplatin represents a viable and effective second-line chemotherapy option for colorectal cancer.
- This strategy expands treatment options beyond traditional 5-FU retreatment.